Transplant Drug Monitoring Assay Market

Transplant Drug Monitoring Assay Market (Product: Consumables and Equipment; and Technology: Chromatography-MS, Immunoassays, and Others - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Transplant Drug Monitoring Assay Market Outlook 2031

  • The global transplant drug monitoring assay market was valued at US$ 198.0 Mn in 2021
  • The global market is projected to advance at a CAGR of 11.0% from 2022 to 2031
  • The global transplant drug monitoring assay market is anticipated to reach more than US$ 542 Mn by the end of 2031

Analysts’ Viewpoint on Transplant Drug Monitoring Assay Market Scenario

Therapeutic drug monitoring (TDM) of transplant medicine plays a crucial role in helping health care professionals maintain plasma and blood levels of immunosuppressants within their respective therapeutic ranges. TDM ensures that concentrations are not too low or too high, thereby minimizing the risks of rejection or toxicity, respectively. Leading players operating in the healthcare industry offer a full line of Immunosuppressant Drug Monitoring (ISD) assays, such as mycophenolic acid, cyclosporine, everolimus, and tacrolimus, to aid in patient monitoring. Rise in healthcare expenditure, improvement in healthcare infrastructure, increase in global per capita income, and government reimbursement programs are likely to create lucrative opportunities for companies operating in the transplant drug monitoring assay market in the next few years.

transplant drug monitoring assay market

Overview of Transplant Drug Monitoring Assay Market

The global transplant drug monitoring assay market is expected to grow at a rapid pace during the forecast period from 2022 to 2031, owing to the increase in need for organ transplantation, surge in R&D funding, and rise in prevalence of chronic liver and kidney diseases. Increase in need for point-of-care therapeutic drug monitoring and home-based therapeutic drug monitoring is likely to create lucrative opportunities for players operating in the global transplant drug monitoring assay market during the forecast period.

Request a sample to get extensive insights into the Transplant Drug Monitoring Assay Market

Rise in Geriatric Population and Increase in Incidence of Chronic Diseases to Drive Market

Rise in incidence of chronic diseases of the liver, heart, kidney, and pancreas along with blood disorders such as leukemia and aplastic anemia are driving the demand for organ transplants/replacements. This is expected to boost the global transplant drug monitoring assay market. According to the Health Resources & Services Administration (HRSA), around 40,000+ transplants were performed across the globe in 2021. According to the World Health Organization (WHO), the global geriatric population stood at around 524 million in 2010 and is anticipated to reach 1.5 billion by 2050. The world is aging at a rapid pace, especially in developed countries such as the U.S., Germany, and Japan. For instance, the U.S. Census Bureau stated in 2010 that people older than 65 years represented around 12.4% of the total population in 2000, and the percentage is expected to reach 19% in the U.S. by 2030. Surge in geriatric population directly affects the growth and demand for organ transplants, primarily due to their higher susceptibility to kidney and heart diseases.

Government Support for Organ Donation to Augment Transplant Drug Monitoring Assay Market

The number of organ donors across the globe has been rising due to the initiatives by government organizations. Various government authorities across developed and developing countries support organ donation through awareness programs, financial assistance, and effective schemes and policies. In April 2022, the Government of Canada announced the investment of US$ 2 Mn for research in innovative organ and tissue donation.

In November 2019, the Spanish Ministry of Health, Consumer Affairs and Social Welfare and the World Health Organization (WHO) signed an agreement for fostering cooperation in the field of donation and transplantation of organs, cells, and tissues. This technical agreement will lead to the creation of the Global Observatory on Donation and Transplantation 'GODT', which will collect and manage global data on clinical and regulatory information regarding organ transplants. Thus, government support for organ donation is expected to create significant opportunities in the global transplant drug monitoring assay market.

Request a custom report on Transplant Drug Monitoring Assay Market

Field-proven Reliability and Efficiency to Drive Equipment Segment

In terms of product, the global transplant drug monitoring assay market has been bifurcated into equipment and consumables. The equipment segment held major share of the global market in 2021. The segment is projected to grow at a rapid pace during the forecast period. Clinical chemistry analyzers and immunoassay analyzers provide mid-to high-volume laboratories the flexibility to improve efficiencies and economics. With a throughput of excellent onboard parameters, this equipment delivers field-proven reliability and efficiency to laboratories worldwide. Additionally, leading players such as Thermo Scientific are coming up with innovative solutions such as ‘QMS Everolimus’. This analyzer carries the CE mark for usage in the European Union for liver transplant drug monitoring.

Growth in Need for Organ Transplantation Globally to Propel Chromatography-MS Segment

Based on technology, the global transplant drug monitoring assay market has been classified into chromatography-MS and immunoassays. Chromatography-MS is a rapidly growing segment of the global transplant drug monitoring assay market. The segment is expected to advance at a CAGR of 12.2% during the forecast period. Growth of the segment can be ascribed to the rise in demand for organ transplantation across the globe. Currently, 121,678 people are waiting for lifesaving organ transplants in the U.S.

FDA Approval as Transplantation Drug to Augment Tacrolimus Segment

Based on drug, the global transplant drug monitoring assay market has been split into tacrolimus, cyclosporin, methotrexate, and others. The tacrolimus segment held major share of the global market in 2021. Recent FDA approval for tacrolimus as a transplantation drug is projected to drive the segment during the forecast period. In July 2021, the U.S. Food and Drug Administration (FDA) approved the usage of the transplant drug tacrolimus for the prevention of organ rejection in pediatric and adult patients receiving lung transplants. Furthermore, nearly 85% of kidney transplant recipients have been prescribed tacrolimus as a maintenance immunosuppressive regimen, primarily due to its higher potency, and lower rejection and nephrotoxicity compared to cyclosporine.

Provision of Transplant Drug Monitoring Services to Drive Hospital Laboratories Segment

Based on end-user, the global transplant drug monitoring assay market has been divided into hospital laboratories, commercial & private laboratories, and others. The hospital laboratories segment held prominent share of the global market in 2021. The segment is likely to expand at the fastest CAGR during the forecast period. TDM assays are increasingly provided in hospitals and ambulatory surgical centers with multiple medical specialties. These services are managed entirely by hospital pharmacists. Hence, these pharmacists assume a crucial role in ensuring the optimal use of TDM assays. Additionally, rise in number of government and private hospital laboratories in emerging economies, such as China and India, and increase in incidence of cardiovascular and chronic liver diseases are driving the segment. Surge in patient base is encouraging hospital laboratories to form alliances and strategic partnerships. This is also likely to propel the segment.

Regional Outlook of Global Transplant Drug Monitoring Assay Market

North America accounted for major share of around 35% of the global transplant drug monitoring assay market in 2021. North America’s dominance can be ascribed to improvements in technology, surgical techniques, and immunosuppressive drugs along with rise in success rate of organ transfer procedures. Additionally, rapid adoption of advanced treatments, increase in R&D activities, high affordability, and rise in prevalence of chronic diseases, including chronic kidney diseases and CVDs, are driving the demand for organ transplantation. This is likely to boost the transplant drug monitoring assay market in North America.

Europe and Asia Pacific are also large markets for transplant drug monitoring assays. These regions held the second and third largest share, respectively, of the global market in 2021. The transplant drug monitoring assay market in Asia Pacific is driven by the rise in focus on organ donation. Strong presence of Siemens Healthineers AG, Hologic, Inc., Danaher Corporation, and Bio-Rad Laboratories, Inc., specifically in China, India, and South Korea, is also expected to augment the market in Asia Pacific. The market in Latin America is projected to grow at a faster pace than that in Middle East & Africa.

Analysis of Key Players in Global Transplant Drug Monitoring Assay Market

The global transplant drug monitoring assay market is consolidated, with the presence of a small number of leading players. Most of the companies are investing significantly in research & development activities, primarily to introduce innovative assays. Furthermore, diversification of product portfolios and mergers & acquisitions are the key strategies adopted by the leading players. Abbott, Thermo Fisher Scientific Inc., H.U. Group Holdings, Inc. (Fujirebio Holdings, Inc.), Hoffmann-La Roche Ltd., Siemens Healthineers AG, Hologic, Inc., Danaher Corporation, and Bio-Rad Laboratories, Inc. are the key players in the transplant drug monitoring assay market.

Key Developments in Global Transplant Drug Monitoring Assay Market

  • On April 21, 2022, H.U. Group Holdings, Inc. and its wholly-owned subsidiary Fujirebio Holdings, Inc. announced the official launch of in-vitro diagnostic "Lumipulse Presto iTACT Tacrolimus". This reagent has been developed specifically for the fully automated chemiluminescence enzyme immunoassay system "Lumipulse L2400", and will be used for the measurement of blood concentration of tacrolimus, which is an immunosuppressant primarily administered to organ transplant patients.
  • In December 2018, Thermo Fisher announced the launch of Plazomicin Immunoassay. The ‘QMS Plazomicin Immunoassay’ is the new addition to the company’s therapeutic drug monitoring product portfolio, which employs proprietary technology across a range of immunosuppressants and other drug classes.

Each of these players has been profiled in the transplant drug monitoring assay market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Transplant Drug Monitoring Assay Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 198.0 Mn

Market Forecast Value in 2031

More than US$ 542 Mn

Growth Rate

(CAGR)

11.0%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Mn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product
    • Equipment
    • Consumables
      • Chromatography & MS Detectors
      • Immunoassay Analyzers
      • Clinical Chemistry Analyzers
  • Technology
    • Chromatography-MS
    • Immunoassays
  • Drug
    • Tacrolimus
    • Methotrexate
    • Cyclosporin
    • Others
  • End-user
    • Hospital Laboratories
    • Commercial & Private Laboratories
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
  • Brazil
  • Mexico
  • Rest of Latin America
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Companies Profiled

  • Abbott
  • Thermo Fisher Scientific, Inc.
  • H.U. Group Holdings, Inc. (Fujirebio Holdings, Inc.)
  • Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG
  • Hologic, Inc.
  • Danaher Corporation
  •  Bio-Rad Laboratories, Inc.
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global transplant drug monitoring assay market in 2021?

The global transplant drug monitoring assay market was valued at US$ 198.0 Mn in 2021.

How big will be the global transplant drug monitoring assay market in 2031?

The global transplant drug monitoring assay market is projected to reach more than US$ 542 Mn by 2031.

What was the CAGR of the global transplant drug monitoring assay market from 2017 to 2021?

The global transplant drug monitoring assay market grew at a CAGR of 1% from 2017 to 2021.

What will be the CAGR of the global transplant drug monitoring assay market during the forecast period (2022–2031)?

The global transplant drug monitoring assay market is anticipated to grow at a CAGR of 11.0% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Increase in incidence of chronic diseases leading to organ failure and technologically advanced products propel the global transplant drug monitoring assay market.

What is the market share of the leading segment of the global transplant drug monitoring assay market?

The tacrolimus segment held over 60% share of the global transplant drug monitoring assay market in 2021.

Who are the prominent players in the global transplant drug monitoring assay market?

Prominent players in the global transplant drug monitoring assay market include Hologic, Inc., Abbott, Thermo Fisher Scientific Inc., H.U. Group Holdings, Inc. (Fujirebio Holdings, Inc.), and Siemens Healthineers AG.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Transplant Drug Monitoring Assay Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Transplant Drug Monitoring Assay Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Pricing Analysis of Drugs (Tacrolimus, Methotrexate and Cyclosporin)

        5.2. Volume Units of Transplant Drugs in 2018-2021 (Tacrolimus, Methotrexate and Cyclosporin)

        5.3. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)

        5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long-term impact)

    6. Global Transplant Drug Monitoring Assay Market Analysis and Forecast, By Product

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Product, 2017–2031

            6.3.1. Consumables

            6.3.2. Equipment

                6.3.2.1. Immunoassay Analyzers

                6.3.2.2. Chromatography & MS Detectors

                6.3.2.3. Clinical Chemistry Analyzers

        6.4. Market Attractiveness Analysis, By Product

    7. Global Transplant Drug Monitoring Assay Market Analysis and Forecast, By Drug

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Drug, 2017–2031

            7.3.1. Tacrolimus

            7.3.2. Methotrexate

            7.3.3. Cyclosporin

            7.3.4. Others

        7.4. Market Attractiveness Analysis, By Drug

    8. Global Transplant Drug Monitoring Assay Market Analysis and Forecast, By Technology

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Technology , 2017–2031

            8.3.1. Immunoassays

            8.3.2. Chromatography-MS

            8.3.3. Others

        8.4. Market Attractiveness Analysis, By Technology

    9. Global Transplant Drug Monitoring Assay Market Analysis and Forecast, By End-user

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by End-user, 2017–2031

            9.3.1. Hospital Laboratories

            9.3.2. Commercial & Private Laboratories

            9.3.3. Others

        9.4. Market Attractiveness Analysis, By End-user

    10. Global Transplant Drug Monitoring Assay Market Analysis and Forecast, By Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness Analysis, By Region

    11. North America Transplant Drug Monitoring Assay Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product, 2017–2031

            11.2.1. Consumables

            11.2.2. Equipment

                11.2.2.1. Immunoassay Analyzers

                11.2.2.2. Chromatography & MS Detectors

                11.2.2.3. Clinical Chemistry Analyzers

        11.3. Market Value Forecast, by Drug, 2017–2031

            11.3.1. Tacrolimus

            11.3.2. Methotrexate

            11.3.3. Cyclosporin

            11.3.4. Others

        11.4. Market Value Forecast, by Technology, 2017–2031

            11.4.1. Immunoassays

            11.4.2. Chromatography-MS

            11.4.3. Others

        11.5. Market Value Forecast, by End-user, 2017–2031

            11.5.1. Hospital Laboratories

            11.5.2. Commercial & Private Laboratories

            11.5.3. Others

        11.6. Market Value Forecast, by Country, 2017–2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Product

            11.7.2. By Drug

            11.7.3. By Technology

            11.7.4. By End-user

            11.7.5. By Country

    12. Europe Transplant Drug Monitoring Assay Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product, 2017–2031

            12.2.1. Consumables

            12.2.2. Equipment

                12.2.2.1. Immunoassay Analyzers

                12.2.2.2. Chromatography & MS Detectors

                12.2.2.3. Clinical Chemistry Analyzers

        12.3. Market Value Forecast, by Drug, 2017–2031

            12.3.1. Tacrolimus

            12.3.2. Methotrexate

            12.3.3. Cyclosporin

            12.3.4. Others

        12.4. Market Value Forecast, by Technology, 2017–2031

            12.4.1. Immunoassays

            12.4.2. Chromatography-MS

            12.4.3. Others

        12.5. Market Value Forecast, by End-user, 2017–2031

            12.5.1. Hospital Laboratories

            12.5.2. Commercial & Private Laboratories

            12.5.3. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Product

            12.7.2. By Drug

            12.7.3. By Technology

            12.7.4. By End-user

            12.7.5. By Country/Sub-region

    13. Asia Pacific Transplant Drug Monitoring Assay Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product, 2017–2031

            13.2.1. Consumables

            13.2.2. Equipment

                13.2.2.1. Immunoassay Analyzers

                13.2.2.2. Chromatography & MS Detectors

                13.2.2.3. Clinical Chemistry Analyzers

        13.3. Market Value Forecast, by Drug, 2017–2031

            13.3.1. Tacrolimus

            13.3.2. Methotrexate

            13.3.3. Cyclosporin

            13.3.4. Others

        13.4. Market Value Forecast, by Technology, 2017–2031

            13.4.1. Immunoassays

            13.4.2. Chromatography-MS

            13.4.3. Others

        13.5. Market Value Forecast, by End-user, 2017–2031

            13.5.1. Hospital Laboratories

            13.5.2. Commercial & Private Laboratories

            13.5.3. Others

        13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Product

            13.7.2. By Drug

            13.7.3. By Technology

            13.7.4. By End-user

            13.7.5. By Country/Sub-region

    14. Latin America Transplant Drug Monitoring Assay Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Product, 2017–2031

            14.2.1. Consumables

            14.2.2. Equipment

                14.2.2.1. Immunoassay Analyzers

                14.2.2.2. Chromatography & MS Detectors

                14.2.2.3. Clinical Chemistry Analyzers

        14.3. Market Value Forecast, by Drug, 2017–2031

            14.3.1. Tacrolimus

            14.3.2. Methotrexate

            14.3.3. Cyclosporin

            14.3.4. Others

        14.4. Market Value Forecast, by Technology , 2017–2031

            14.4.1. Immunoassays

            14.4.2. Chromatography-MS

            14.4.3. Others

        14.5. Market Value Forecast, by End-user, 2017–2031

            14.5.1. Hospital Laboratories

            14.5.2. Commercial & Private Laboratories

            14.5.3. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Product

            14.7.2. By Drug

            14.7.3. By Technology

            14.7.4. By End-user

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Transplant Drug Monitoring Assay Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Product, 2017–2031

            15.2.1. Consumables

            15.2.2. Equipment

                15.2.2.1. Immunoassay Analyzers

                15.2.2.2. Chromatography & MS Detectors

                15.2.2.3. Clinical Chemistry Analyzers

        15.3. Market Value Forecast, by Drug, 2017–2031

            15.3.1. Tacrolimus

            15.3.2. Methotrexate

            15.3.3. Cyclosporin

            15.3.4. Others

        15.4. Market Value Forecast, by Technology , 2017–2031

            15.4.1. Immunoassays

            15.4.2. Chromatography-MS

            15.4.3. Others

        15.5. Market Value Forecast, by End-user, 2017–2031

            15.5.1. Hospital Laboratories

            15.5.2. Commercial & Private Laboratories

            15.5.3. Others

        15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Product

            15.7.2. By Drug

            15.7.3. By Technology

            15.7.4. By End-user

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player - Competition Matrix (by tier and size of companies)

        16.2. Market Share Analysis, by Company, 2021

        16.3. Company Profiles

            16.3.1. Abbott

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Company Financials

                16.3.1.3. Growth Strategies

                16.3.1.4. SWOT Analysis

            16.3.2. Thermo Fisher Scientific, Inc.

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Company Financials

                16.3.2.3. Growth Strategies

                16.3.2.4. SWOT Analysis

            16.3.3. H.U. Group Holdings Inc. (Fujirebio Holdings, Inc.)

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Company Financials

                16.3.3.3. Growth Strategies

                16.3.3.4. SWOT Analysis

            16.3.4. Hoffmann-La Roche Ltd.

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Company Financials

                16.3.4.3. Growth Strategies

                16.3.4.4. SWOT Analysis

            16.3.5. Siemens Healthineers AG

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Company Financials

                16.3.5.3. Growth Strategies

                16.3.5.4. SWOT Analysis

            16.3.6. Hologic, Inc.

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Company Financials

                16.3.6.3. Growth Strategies

                16.3.6.4. SWOT Analysis

            16.3.7. Danaher Corporation

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Company Financials

                16.3.7.3. Growth Strategies

                16.3.7.4. SWOT Analysis

            16.3.8. Bio-Rad Laboratories, Inc.

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Company Financials

                16.3.8.3. Growth Strategies

                16.3.8.4. SWOT Analysis

    List of Tables

    Table 01: Global Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 02: Global Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Equipment, 2017–2031

    Table 03: Global Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 04: Global Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Drug, 2017–2031

    Table 05: Global Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 06: Global Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 07: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 08: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 09: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Equipment, 2017–2031

    Table 10: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 11: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Drug, 2017–2031

    Table 12: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 13: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 15: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Equipment, 2017–2031

    Table 16: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 17: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Drug, 2017–2031

    Table 18: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 19: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 20: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 21: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Equipment, 2017–2031

    Table 22: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 23: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Drug, 2017–2031

    Table 24: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 25: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 26: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 27: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Equipment, 2017–2031

    Table 28: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 29: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Drug, 2017–2031

    Table 30: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 31: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 32: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 33: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Equipment, 2017–2031

    Table 34: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 35: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Drug, 2017–2031

    Table 36: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Global Transplant Drug Monitoring (TDM) Assay Market, by Product, 2021 and 2031

    Figure 02: Global Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Product, 2022–2031

    Figure 03: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Consumables, 2017–2031

    Figure 04: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Equipment, 2017–2031

    Figure 05: Global Transplant Drug Monitoring (TDM) Assay Market, by Technology, 2021 and 2031

    Figure 06: Global Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 07: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Immunoassays, 2017–2031

    Figure 08: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Chromatography-MS, 2017–2031

    Figure 09: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Others, 2017–2031

    Figure 10: Global Transplant Drug Monitoring (TDM) Assay Market, by Drug, 2021 and 2031

    Figure 11: Global Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Drug, 2022–2031

    Figure 12: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Tacrolimus, 2017–2031

    Figure 13: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Methotrexate, 2017–2031

    Figure 14: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Cyclosporin, 2017–2031

    Figure 15: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Others, 2017–2031

    Figure 16: Global Transplant Drug Monitoring (TDM) Assay Market, by End-user, 2021 and 2031

    Figure 17: Global Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 18: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Hospital Laboratories, 2017–2031

    Figure 19: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Commercial & Private Laboratories, 2017–2031

    Figure 20: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Others, 2017–2031

    Figure 21: Global Transplant Drug Monitoring (TDM) Assay Market, by Region, 2021 and 2031

    Figure 22: Global Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Region, 2022–2031

    Figure 23: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, 2017–2031

    Figure 24: North America Transplant Drug Monitoring (TDM) Assay Market, by Country, 2021 and 2031

    Figure 25: North America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Country, 2022–2031

    Figure 26: North America Transplant Drug Monitoring (TDM) Assay Market, by Product, 2021 and 2031

    Figure 27: North America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Product, 2022–2031

    Figure 28: North America Transplant Drug Monitoring (TDM) Assay Market, by Technology, 2021 and 2031

    Figure 29: North America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 30: North America Transplant Drug Monitoring (TDM) Assay Market, by Drug, 2021 and 2031

    Figure 31: North America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Drug, 2022–2031

    Figure 32: North America Transplant Drug Monitoring (TDM) Assay Market, by End-user, 2021 and 2031

    Figure 33: North America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 34: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, 2017–2031

    Figure 35: Europe Transplant Drug Monitoring (TDM) Assay Market, by Country/Sub-region, 2021 and 2031

    Figure 36: Europe Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 37: Europe Transplant Drug Monitoring (TDM) Assay Market, by Product, 2021 and 2031

    Figure 38: Europe Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Product, 2022–2031

    Figure 39: Europe Transplant Drug Monitoring (TDM) Assay Market, by Technology, 2021 and 2031

    Figure 40: Europe Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 41: Europe Transplant Drug Monitoring (TDM) Assay Market, by Drug, 2021 and 2031

    Figure 42: Europe Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Drug, 2022–2031

    Figure 43: Europe Transplant Drug Monitoring (TDM) Assay Market, by End-user, 2021 and 2031

    Figure 44: Europe Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 45: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, 2017–2031

    Figure 46: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market, by Country/Sub-region/Sub-region, 2021 and 2031

    Figure 47: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 48: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market, by Product, 2021 and 2031

    Figure 49: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Product, 2022–2031

    Figure 50: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market, by Technology, 2021 and 2031

    Figure 51: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 52: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market, by Drug, 2021 and 2031

    Figure 53: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Drug, 2022–2031

    Figure 54: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market, by End-user, 2021 and 2031

    Figure 55: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 56: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, 2017–2031

    Figure 57: Latin America Transplant Drug Monitoring (TDM) Assay Market, by Country/Sub-region, 2021 and 2031

    Figure 58: Latin America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 59: Latin America Transplant Drug Monitoring (TDM) Assay Market, by Product, 2021 and 2031

    Figure 60: Latin America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Product, 2022–2031

    Figure 61: Latin America Transplant Drug Monitoring (TDM) Assay Market, by Technology, 2021 and 2031

    Figure 62: Latin America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 63: Latin America Transplant Drug Monitoring (TDM) Assay Market, by Drug, 2021 and 2031

    Figure 64: Latin America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Drug, 2022–2031

    Figure 65: Latin America Transplant Drug Monitoring (TDM) Assay Market, by End-user, 2021 and 2031

    Figure 66: Latin America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 67: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, 2017–2031

    Figure 68: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market, by Country/Sub-region, 2021 and 2031

    Figure 69: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 70: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market, by Product, 2021 and 2031

    Figure 71: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Product, 2022–2031

    Figure 72: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market, by Technology, 2021 and 2031

    Figure 73: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 74: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market, by Drug, 2021 and 2031

    Figure 75: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Drug, 2022–2031

    Figure 76: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market, by End-user, 2021 and 2031

    Figure 77: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 78: Global Transplant Drug Monitoring (TDM) Assay Market Share Analysis/Ranking, by Company, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved